Topics

Articles

Product is powered by company’s Opus platform

TraceLink Unveils Multi-enterprise Supply Chain Work Management Solution

Reportedly provides 270 hours of independent runtime for temperature-sensitive pharma transportation

SkyCell Unveils 1500X Hybrid Container 

Karina Castagna is SVP Specialty Solutions at OptimizeRx.

What does digital innovation actually mean and how is it changing the way that pharma is interacting with HCPs and patients?

Engaging HCPs to Improve Brand Access and Retention with Digital Point of Care and Sales Technology

David Laros is Vice President of Digital Strategy, Analytics and I﻿nsights at 

To unlock the full potential of new patient support tools, pharma companies must recognize the crucial role advanced analytics plays in facilitating enhanced patient engagement that yields improved adherence. 

The Analytics Backbone of Next-Gen Patient Support

Aims to increase presence in affordability market

Rx Holdings Purchases Biocel Access Solutions

Guy Levy-Yurista, PhD, is CEO of Synthace.

How CDMOs will lead the way toward true cloud lab enablement

Setting Science Free

Crēdo ProEnvision Software 2.0, company says, expected to improve the customer experience for cold chain clients

Peli BioThermal Enhances Its Track-and-Trace Program

Among benefits, Expanded Access software can reportedly help design more effective clinical trials and capture RWD

MedaSystems Raises $1.5 Million Toward Furthering Patient Access to Investigational Therapies 

Alan Kalton is Senior Vice President of sales for Aktana and GM of Aktana’s European division. His 27-year career balances global consulting with multiple industries in AI, technology, and analytics with life sciences industry experience working with leading pharmaceutical and medical technology companies. Kalton currently resides in Barcelona, Spain, Aktana’s headquarters for European service operations.
He can be reached at alan.kalton@aktana.com

Small and emerging biopharma have been historically reserved about artificial intelligence. But, writes Alan Kalton, AI solutions have matured, been proven, and are no longer a risky investment for small to mid-size companies.

Democratizing AI: Bridging the Intelligence Divide in Commercial Life Sciences

Sara Goldman is VP Patient Engagement at 

Taking advantage of new advances in tech-driven engagement to boost patient
support and adherence

Data and Technology